ArticleFrontiers in endocrinology2025
Is it possible to rule out level II and level VB dissection in patients with metastatic papillary thyroid cancer?
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The completeness of surgical resection is a key factor influencing outcomes in patients with papillary thyroid carcinoma (PTC) and regional lymph node metastases. However, the optimal extent of therapeutic lateral neck dissection remains a matter of debate This study aimed to assess the diagnostic accuracy of preoperative ultrasonography (US) in detecting lateral lymph node metastasis (LLNM) in patients with PTC and to identify clinical and pathological factors predictive of metastases at levels II and V. Methods: This retrospective study included consecutive patients with PTC who underwent comprehensive lateral neck dissection at a single tertiary center between June 2020 and July 2024. Results: In 63 patients, a total of 78 comprehensive lateral neck dissections were performed. Of the patients, 41 (65%) were male and 22 (35%) were female, with a median age of 37 years (range, 24-49 years). Lymph node metastases were identified in 46 (58.9%), at level II, 561 (78.2%) at level III, 60 (76.9%) at level IV, and 9 (11.5%) at level Vb. Metastasis to level IIb was detected in 5 dissections. Among the 9 patients with level Vb metastases, 7 (77.8%) had involvement of four different cervical levels. The specificity of US in identifying metastatic disease was notably high at both level II (80%) and level Vb (87%). Independent predictors of metastatic involvement at level II and level Vb lymph nodes was associated with extrathyroidal extension [level II: odds ratio (OR) 7.88, p=0.03; level V: OR 6.91, p=0.043] and a largest metastatic lateral lymph node size above 2 cm [level II: OR 18.58, p=0.03; level V: OR 11.32, p=0.03]. Conclusion: Routine dissection of level IIa is recommended in N1b PTC due to high metastasis rates. However, level IIb dissection may be omitted in selected cases given its low metastasis rate and potential morbidity, with intraoperative frozen section serving as a useful guide. Similarly, level Vb dissection may be avoided when lateral lymph nodes are <2 cm, multilevel involvement is absent, and ultrasonographic findings are negative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.